Acadia Healthcare (ACHC) Expected to Announce Earnings on Tuesday

Acadia Healthcare (NASDAQ:ACHC) is projected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Acadia Healthcare to post earnings of $0.70 per share and revenue of $839.59 million for the quarter. Acadia Healthcare has set its FY 2025 guidance at 2.500-2.800 EPS.

Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.05. The business had revenue of $770.51 million for the quarter, compared to analysts’ expectations of $769.90 million. Acadia Healthcare had a net margin of 5.94% and a return on equity of 8.72%. The business’s revenue was up .3% on a year-over-year basis. During the same quarter last year, the company earned $0.84 EPS. On average, analysts expect Acadia Healthcare to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Acadia Healthcare Price Performance

Shares of NASDAQ ACHC opened at $21.09 on Friday. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of 10.39, a PEG ratio of 4.02 and a beta of 0.88. Acadia Healthcare has a 12 month low of $20.35 and a 12 month high of $82.40. The firm’s 50 day simple moving average is $22.49 and its 200-day simple moving average is $28.59. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.35 and a quick ratio of 1.35.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Stephens raised shares of Acadia Healthcare to a “hold” rating in a research note on Monday, June 2nd. Mizuho dropped their price objective on shares of Acadia Healthcare from $37.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 14th. KeyCorp dropped their price target on shares of Acadia Healthcare from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Acadia Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Finally, Barclays reduced their price objective on shares of Acadia Healthcare from $35.00 to $28.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Acadia Healthcare has a consensus rating of “Hold” and an average price target of $47.94.

Institutional Investors Weigh In On Acadia Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Acadia Healthcare by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company’s stock worth $10,337,000 after purchasing an additional 27,207 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Acadia Healthcare by 21.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company’s stock worth $21,170,000 after purchasing an additional 121,444 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Acadia Healthcare during the 1st quarter worth $1,600,000.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.